Compare GBIO & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBIO | RGC |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 9.8B |
| IPO Year | 2020 | 2021 |
| Metric | GBIO | RGC |
|---|---|---|
| Price | $5.60 | $33.60 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.88 | N/A |
| AVG Volume (30 Days) | 76.1K | ★ 823.6K |
| Earning Date | 11-05-2025 | 10-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $0.09 |
| 52 Week High | $10.40 | $83.60 |
| Indicator | GBIO | RGC |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 55.31 |
| Support Level | $5.31 | $34.00 |
| Resistance Level | $5.70 | $69.00 |
| Average True Range (ATR) | 0.18 | 9.06 |
| MACD | 0.01 | 1.44 |
| Stochastic Oscillator | 69.57 | 27.54 |
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.